Celadon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Celadon Pharmaceuticals has a total shareholder equity of £2.5M and total debt of £31.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are £8.5M and £6.0M respectively.
Key information
1.3%
Debt to equity ratio
UK£31.00k
Debt
| Interest coverage ratio | n/a |
| Cash | UK£16.00k |
| Equity | UK£2.45m |
| Total liabilities | UK£6.01m |
| Total assets | UK£8.46m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CEL's short term assets (£1.7M) exceed its short term liabilities (£878.0K).
Long Term Liabilities: CEL's short term assets (£1.7M) do not cover its long term liabilities (£5.1M).
Debt to Equity History and Analysis
Debt Level: CEL's net debt to equity ratio (0.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CEL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CEL has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CEL is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.